211

Last update : 10/20/2017

LYCOLL - Cross-sectional study of year-10 and year-11 students: influence of a change of environmental context on high-risk behaviours

Head : Binder Philippe

Main objective

To study the influence of change in environmental context on the consumption of psychoactive products and on other high-risk behaviours, such as suicide. To describe the conditions of social and family life, education, health condition and associated behaviours.

Inclusion criteria

Students in year 10 and 11 assimilated in Charente-Maritime.

Last update : 10/20/2017

EMES - Pragmatic pharmacoeconomic assessment of Sinovial® in the treatment of gonarthrosis

Head : Moore Nicholas, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen

Version 1

212

Last update : 09/05/2017

EMES - Pragmatic pharmacoeconomic assessment of Sinovial® in the treatment of gonarthrosis

Head : Moore Nicholas, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen

Main objective

The objective was to compare the cost of two therapeutic strategies: Sinovial® and other care versus other care alone.

Inclusion criteria

Patient agreed to participate in this study and having signed the consent form; Patient having had a first injection of Sinovial® between 01/01/2003 and 31/03/2003; Patient having never previously received viscosupplementation treatment; Patient aged 20 years and over; Patient affiliated to the general health insurance system for at least 12 months at the time of first injection

Last update : 09/05/2017

KARU-PROSTATE - Case-Control Study on the Impact of Chlordecone Exposure and Risk of Prostate Cancer in the West Indies

Head : Multigner Luc , U1085 Research Institute of Health, Environment and Work

Version 1

213

Last update : 09/05/2017

KARU-PROSTATE - Case-Control Study on the Impact of Chlordecone Exposure and Risk of Prostate Cancer in the West Indies

Head : Multigner Luc , U1085 Research Institute of Health, Environment and Work

Main objective

To identify the environmental and genetic risk factors of prostate cancer and to assess the impact of chlordecone exposure in the onset of the disease.

Inclusion criteria

– Male
– Adult
– Caribbean native (Guadeloupe, Martinique, Haiti, Dominica)

Last update : 09/05/2017

NutriMay - Food, Nutrition and Health in Mayotte: 2006 NutriMay Study

Head : Deschamps Valerie, Unité de surveillance et d’épidémiologie nutritionnelle

Version 1

214

Last update : 09/05/2017

NutriMay - Food, Nutrition and Health in Mayotte: 2006 NutriMay Study

Head : Deschamps Valerie, Unité de surveillance et d’épidémiologie nutritionnelle

Main objective

To describe food consumption, physical activity and nutrition status of the population living in Mayotte, with particular focus on children under 5 years old and women of childbearing age.

Inclusion criteria

Individuals living in an ordinary household in Mayotte and capable of understanding the aims of the study.

Last update : 09/05/2017

EUROPOP - European programme on the relationship between occupational risks and premature births

Head : Ancel Pierre-Yves, U953 - Unité de recherche épidémiologique en santé périnatale et santé des femmes et des enfants

Version 1

215

Last update : 09/05/2017

EUROPOP - European programme on the relationship between occupational risks and premature births

Head : Ancel Pierre-Yves, U953 - Unité de recherche épidémiologique en santé périnatale et santé des femmes et des enfants

Main objective

Consider the effect of particular work conditions on premature birth.

Inclusion criteria

woman - adult - childbirth 22-36 weeks amenorrhea

Last update : 09/05/2017

ARCHIMED VILLE - Prevention of venous thromboembolic events with Arixtra 2.5mg for medical ill patients in general practice

Head : Leclerc-Zwirn Christel, Laboratoire GSK

Version 1

216

Last update : 01/01/2020

ARCHIMED VILLE - Prevention of venous thromboembolic events with Arixtra 2.5mg for medical ill patients in general practice

Head : Leclerc-Zwirn Christel, Laboratoire GSK

Main objective

Evaluate the average duration of treatment via ARIXTRA® 2.5 mg with thromboprophylaxis in ambulatory general practice

Inclusion criteria

Patient of at least 18 years of age,
-bedridden or with reduced mobility,
-for whom a treatment via ARIXTRA® 2.5 mg is initiated with thromboprophylaxis.

Last update : 01/01/2020